# Bristol Myers Squibb announces U.S. FDA Breakthrough Therapy Designation for investigational LPA1 antagonist for progressive pulmonary fibrosis
**FDA Update**

**2023-10-24 11:24**

**https://www.ainvest.com/news/bristol-myers-squibb-announces-u-s-fda-breakthrough-therapy-designation-for-investigational-lpa1-antagonist-for-progressive-pulmonary-fibrosis-231010002c4a298b172f49bf/**

Bristol Myers Squibb announces U.S. FDA Breakthrough Therapy Designation for investigational LPA1 antagonist for progressive pulmonary fibrosis